Online:
Visits:
Stories:

By Sam@mrc
Contributor profile | More stories

Story Views
Now:
Last Hour:
Last 24 Hours:
Total:

Chemotherapy-induced Nausea and Vomiting Drugs Market Size, Share, Demand and Forecast to 2021

Thursday, March 9, 2017 2:50

% of readers think this story is Fact. Add your two cents.

(Before It's News)

Market Research Analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

According to the report, the high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.

Download Sample Report @ https://marketreportscenter.com/request-sample/494138

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The market is divided into the following segments based on geography:

Americas
APAC
EMEA

Technavio’s report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro

Other prominent vendors
Acacia Pharma
Aphios
Baxter Healthcare
Dr. Reddy’s Laboratories
Eisai
Especificos Stendhal
F. Hoffmann-La Roche
Kyowa Hakko Kirin
ees Pharmaceutical Holdings
Midatech Pharma
Mundipharma
Mylan
Ono Pharmaceutical
OPKO Health
Orchid Chemicals & Pharmaceuticals
Otsuka Pharmaceutical
Purdue Pharma
Sandoz (a subsidiary of Novartis)
SciClone Pharmaceuticals
Shin Nippon Biomedical Laboratories
Solasia Pharma K.K.
Specialised Therapeutics
Sun Pharma
Taiho Pharmaceutical
Teva Pharmaceuticals

Market driver
Growing preference of chemotherapy drugs in developing countries
For a full, detailed list, view our report

Market challenge
Growing popularity of alternate therapies for the treatment of cancer in developed countries
For a full, detailed list, view our report

Market trend
Increasing inorganic growth strategies likely to fuel the market growth
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://marketreportscenter.com/reports/494138/global-chemotherapy-induced-nausea-and-vomiting-drugs-market-2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights